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sion (HADS) and Medical Research Council and Baseline and 
Transition Dyspnea Index scores.  Results: Compared to 
baseline, there were significant (p  ! 0.05) improvements in 
6MWD, Wmax and muscle strength immediately after reha-
bilitation, and these were maintained over 12 months (p  ! 
0.05). Effects were less pronounced in asbestosis. Overall, a 
significant reduction in the rate of exacerbations by 35%, an-
tibiotic therapy by 27% and use of health care services by 
17% occurred within 12 months after rehabilitation. No 
changes were seen in the questionnaire outcomes.  Conclu-
sions: Pulmonary rehabilitation is effective even in the com-
plex settings of occupational respiratory diseases, providing 
sustained improvement of functional capacity and reducing 
health care utilization.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Pulmonary rehabilitation is an established component 
in the therapy of patients with chronic obstructive pul-
monary disease (COPD)  [1] . The main goals are improve-
ment of exercise capacity, maintenance of independent 
function in daily life and reduction of respiratory symp-
toms. While the efficacy has been demonstrated in 
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 Abstract 
 Background: Pulmonary rehabilitation is a well-recognized 
treatment option in chronic obstructive lung disease im-
proving exercise performance, respiratory symptoms and 
quality of life. In occupational respiratory diseases, which 
can be rather cost-intensive due to the compensation needs, 
very little information is available.  Objectives: This study 
aims at the evaluation of the usefulness of pulmonary reha-
bilitation in patients with occupational respiratory diseases, 
partly involving complex alterations of lung function and of 
the sustainability of effects.  Methods: We studied 263 pa-
tients with occupational respiratory diseases (asthma, silico-
sis, asbestosis, chronic obstructive pulmonary disease) using 
a 4-week inpatient rehabilitation program and follow-up ex-
aminations 3 and 12 months later. The outcomes evaluated 
were lung function, 6-min walking distance (6MWD), maxi-
mum exercise capacity (Wmax), skeletal muscle strength, re-
spiratory symptoms, exacerbations and associated medical 
consultations, quality of life (SF-36, SGRQ), anxiety/depres-
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COPD, the effects are less clear in other respiratory dis-
eases such as fibrosis or asthma  [2–6] .
 In Germany, the most frequent occupational respira-
tory diseases are asthma induced by allergens or toxic 
substances, pneumoconiosis due to inhalation of asbestos 
or silicate dust, and COPD in coal miners. The underly-
ing functional impairments are reversible or irreversible 
airway obstruction, restrictive lung disorders, or a com-
plex combination. As a part of their duties the social ac-
cident insurances enforce tertiary prevention using all 
appropriate means including rehabilitation.
 This longitudinal study evaluated short- and long-
term effects of a pulmonary rehabilitation program per-
formed in two specialized German rehabilitation clinics, 
Falkenstein and Bad Reichenhall, both operated by social 
accident insurances.
 Methods 
 Study Design and Subjects 
 The study was a longitudinal prospective clinical trial with 
pre-to-post comparisons. Inpatient rehabilitation lasted 4 weeks. 
Baseline evaluation was performed during the first 2 days of ad-
mission (abbreviated as T1/T2), and final examination on the last 
day (T3). Subjects were encouraged to maintain their physical ac-
tivity after discharge, without being offered a maintenance pro-
gram. Two follow-up examinations, after 3 (T4) and 12 months 
(T5), were conducted in the same clinic in which the patients had 
undergone rehabilitation.
 The recruiting criteria were: (a) recognized occupational re-
spiratory disease diagnosed as asthma, asbestosis, silicosis or 
COPD in coal miners, (b) reduction in earning capacity by 20–
50%, (c) age  ^  70 years, (d) no rehabilitation in the previous 2 
years, (e) maximum exercise capacity of at least 40 W and (f) no 
progressive malignant diseases.
 This study was approved by DGUV according to official ethic 
regulations (Project No. FFFB0094). Patients gave their informed 
consents.
 Rehabilitation Program 
 Duration, type of training and minimum number of training 
sessions were pre-defined in order to standardize the rehabilita-
tion program. Subjects were excluded if they did not complete the 
minimum numbers:
 The program was individually tailored. Training workload 
started at 60% of baseline ergometer maximum load. The training 
was supervised and duration and workload were adapted to pro-
gression. Peripheral muscles of the upper and lower extremities 
were trained to the same degree on fitness devices.
 Assessments 
 On all study days the same data were collected; the assess-
ments are listed in  table 1 . The prevalence of exacerbations and 
use of health care services within the 12 months before and after 
rehabilitation were assessed at T1/T2 and T5.
 Statistical Analysis 
 For data description, absolute and relative frequencies as well 
as mean values and standard deviations (SD), ranges or standard 
errors of mean (SEM) were computed. At baseline, subgroups 
were compared with each other using one-way analysis of vari-
ance (ANOVA) and   2 tests of contingency tables.
 To evaluate intraindividual changes over time, values of con-
tinuous variables were compared using repeated measures analy-
sis of variance (ANOVA). If overall differences were statistically 
significant, appropriate post hoc multiple comparisons were 
made using the Student-Newman-Keuls multiple range test. The 
total group and the individual groups (asthma, asbestosis, silico-
sis, COPD) were analyzed. The adequacy and admissibility of 
ANOVA was checked by standard procedures regarding data dis-
tributions and residuals. 
 The Wilcoxon signed rank matched-pairs test was used to 
compare the rates of secondary outcomes within the 12-month 
periods before and after rehabilitation. 
 Statistical significance was defined as p  ! 0.05. All analyses 
were performed with SAS software (version 9.2; SAS Institute Inc., 
Cary, N.C., USA).
 Results 
 Between 2007 and 2010, 263 patients completed a 
4-week inpatient pulmonary rehabilitation program as 
well as two follow-up evaluations up to 1 year after inter-
vention. The characteristics of the patient groups are 
shown in  table 2 . There were significantly fewer females 
in all subgroups (p  ! 0.05 for each); 80% of the ever-smok-
ers had quit smoking at least 1 year before intervention.
 In  tables 3 a–d, baseline data (T1/T2) describing exer-
cise capacity, quality of life and dyspnea are presented, as 
well as data at the end of rehabilitation (T3) and the fol-
low-up evaluations after 3 (T4) and 12 months (T5). At 
baseline the percent predicted forced vital capacity 
(FVC%pred) was significantly (p  ! 0.05) lower in asbes-
tosis, while the percent predicted forced expiratory vol-
ume in 1 second (FEV 1 %pred) was similar in all groups. 
Six-minute walking distance (6MWD) was shorter in 
COPD and silicosis patients compared to the two other 
groups (p  ! 0.05 for each). Overall, the participants exhib-
ited mild to moderate impairment of lung function and 
Session-type Number of 
sessions
Endurance-training (treadmill or ergometer) 17
Gymnastics 15
Skeletal muscle strength training 10
Nordic walking 9
Breathing exercises 8
Relaxing techniques 7
Nutritional education 2
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physical performance, while psychological well-being was 
markedly reduced. 
 Acute Effects 
 Immediately after rehabilitation (T3 vs. T1/T2) all 
disease groups showed statistically significant (p  ! 0.05, 
ANOVA) improvements in maximum exercise capacity 
(Wmax), quadriceps and handgrip force ( table  3 a–d). 
The absolute magnitudes of improvement were similar 
in all groups, but the relative gains were greater in silico-
sis and COPD due to the lower baseline values. 6MWD 
increased significantly in all groups except asbestosis
(p  ! 0.05 for each). The changes in lung function mea-
sures and respiratory muscle function were not statisti-
cally significant.
 The hospital anxiety and depression scale (HADS) 
questionnaire showed a significant reduction in anxiety 
immediately after rehabilitation (T3) in all groups ( ta-
ble  3 a–d). Both subscales of the 36-Item Short Form 
Health Survey (SF-36) questionnaire improved only in 
asthma patients (p  ! 0.05;  table 3 a). The scores of the fol-
lowing three questionnaires did not change significantly: 
St. Georges Respiratory Questionnaire (SGRQ), Medical 
Research Council dyspnea scale (MRC) and Baseline and 
Transition Dyspnea Index (BDI/TDI).
 Long-Term Effects 
 Patients with asthma and COPD ( table 3 a, d) showed 
significant long-lasting improvements of peripheral mus-
Table 1.  Tests, questionnaires and other measures used to deter-
mine the effects of rehabilitation in the study
Type of test Measures assessed
Spirometry (Master Screen Body, 
Care Fusion, Germany)
FEV1, FVC, VC, 
Tiffeneau index; using 
standard quality criteria
Respiratory muscle force
(Master Screen Body, Care Fusion, 
Germany)
Pimax, P0,1; as indices of 
potential limitation
in respiratory muscle 
function and load
6-minute walking test according to
ATS-guidelines, 30 m oval parcour
(Pulsoximeter, Konica/Minolta, 
Japan)
6MWD, 
Borg-scale, heart rate, 
O2-saturation before and 
after test 
Ergometer (Master Screen CPX,
Care Fusion, Germany; e-Bike Basic 
PC Plus-Ctrl, ergoline GmbH, 
Germany) starting at 30 W,
increased by 20 W every 2 min
until symptom limitation 
Wmax, heart rate and 
blood pressure 
continuously; arterial 
blood gases and lactate 
before and at maximum 
workload 
Handgrip force by hydraulic hand 
dynamometer (Jamar, Sammons 
Preston Inc., Ont., Canada)
Best of 3 tests, results in 
kilograms 
Quadriceps force (DigiMax
Muskelfunktionstest,
Mechatronic, Germany)
Maximum isometric knee
extension, hip and knee 
in 90° flexion, best of 3 
tests, results in kilograms 
Health-related quality of life SF-36
SGRQ
HADS
Dyspnea MRC 
BDI, TDI
Respiratory infections/exacerbations Self-reported number of 
incidents in the 12 
months before and after 
rehabilitation
Doctors consultations
Antibiotic courses
Hospital admissions 
FEV1 = Forced expiratory volume in 1 second; FVC = forced 
vital capacity; T iffeneau index = ratio of FEV1 to FVC; Pimax = 
maximum inspiratory pressure; P0,1 = pressure 1,200 ms af-
ter normal inspiration; 6MWD = 6-minute walking distance 
Wmax = maximum work load; SF-36 = 36-Item Short Form 
Health Survey; SGRQ = St. George’s Respiratory Questionnaire; 
HADS = Hospital Anxiety and Depression Scale; MRC = Medical 
Research Council Dyspnea Scale; BDI, TDI = Baseline and Tran-
sition Dyspnea Index.
Table 2.  Baseline characteristics of patients
Patient characteristics Value
Total, n 263
Gender (female/male), n 22/241
Age, years 64 (35–77)
Asthma, n 121
Asbestosis, n 66
Silicosis, n 42
COPD, n 34
MdE 27.9 (20–50)
Nonsmoker, n 85
Ex-smoker <20 PY, n 57
Ex-smoker ≥20 PY, n 71
Current smoker (mean 33 PY), n 44
BMI 29.1 (19.2–56.9)
A bsolute numbers or mean values and ranges (in parentheses) 
are given. MdE = Reduction of earning capacity; PY = pack years.
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cle force, Wmax and 6MWD over the follow-up period of 
12 months (T5 vs. T1/2). The effects for patients with as-
bestosis ( table  3 c) were smaller: muscle force was en-
hanced over 12 months (T5 vs. T1/2, p  ! 0.05), improve-
ments of Wmax lasted only until the first follow-up at 3 
months (T4 vs. T1/2, p  ! 0.05) and 6MWD did not change 
significantly. The results for patients with silicosis ( ta-
ble 3 b) varied, revealing responses similar to asthma and 
COPD regarding muscle force and Wmax, but the im-
provement in 6MWD lasted only until the first follow-up 
(p  ! 0.05). Lung function measures and respiratory mus-
cle function did not significantly change over time.
 Table 3. Acute and long-term results of rehabilitation in the four patient groups
a Results in asthma patients
Asthma (n = 121)
T1/T2 T3 T4 T5
FEV1%pred 82.0 (22.1) 80.8 (21.6) 80.0 (22.9) 79.7 (22.6)
FVC%pred 96.2 (19.8) 96.0 (19.5) 96.8 (20.4) 95.7 (20.1)
Tiffeneau, %pred 85.4 (14.0) 85.7 (14.4) 84.7 (15.1) 85.6 (14.6)
Pimax 7.5 (3.0) 7.2 (3.0) 7.6 (2.9) 7.5 (3.0)
P0,1/Pimax 0.03 (0.02) 0.04 (0.02) 0.04 (0.02) 0.04 (0.03)
6MWD, m 511.3 (90.7) 534.6 (81.7)** 532.1 (80.9)** 522.1 (82.2)**
Borg 6MWD 3.9 (2.0) 3.9 (1.9) 4.0 (2.1) 4.5 (1.9)**
Wmax, W 117.0 (38.9) 128.3 (40.8)** 127.6 (41.4)** 124.9 (43.1)**
Quadriceps force, kg 64.4 (24.7) 77.2 (28.2)** 78.3 (29.0)** 74.0 (28.9)**
Handgrip force, kg 70.2 (19.9) 80.0 (21.1)** 79.4 (19.8)** 78.1 (19.9)**
HADS anxiety 11.8 (3.1) 9.6 (1.9)** 11.7 (2.5) 11.5 (2.7)
HADS depression 9.7 (1.8) 9.7 (1.6) 10.0 (2.0) 10.0 (1.8)
SF-36 physical 36.5 (10.6) 39.0 (10.2)** 39.0 (10.4)** 37.5 (10.0)
SF-36 psychomental 46.8 (12.0) 49.9 (10.4)** 46.7 (11.4) 46.2 (11.3)
SGRQ-total score 60.2 (11.6) 60.4 (12.0) 61.1 (10.8) 60.3 (11.3)
MRC 1.8 (1.0) 1.8 (1.0) 1.8 (1.0) 1.8 (1.0)
BDI/TDI 6.75 (2.46) 6.34 (3.44) 5.83 (4.62) 5.09 (5.44)
b Results in silicosis patients
Silicosis (n = 42)
T1/T2 T3 T4 T5
FEV1%pred 79.9 (16.8) 79.2 (19.2) 79.4 (17.9) 78.7 (19.9)
FVC%pred 92.2 (16.5) 91.4 (18.0) 94.0 (15.2) 93.3 (18.0)
Tiffeneau, %pred 88.7 (13.4) 89.3 (13.9) 88.7 (16.2) 88.8 (15.9)
Pimax 6.4 (2.4) 6.1 (2.5) 6.4 (2.6) 6.0 (2.6)
P0,1/Pimax 0.03 (0.02) 0.04 (0.02) 0.03 (0.02) 0.04 (0.02)
6MWD, m 457.8 (75.1) 477.4 (68.7)** 471.9 (66.3)** 461.1 (70.3)
Borg 6MWD 4.2 (1.8) 4.6 (2.3) 4.5 (2.1) 5.2 (2.3)*
Wmax, W 108.3 (30.2) 117.6 (27.7)** 117.6 (27.6)** 118.3 (26.7)**
Quadriceps force, kg 57.8 (20.9) 73.4 (25.4)** 74.1 (25.5)** 71.0 (24.1)**
Handgrip force, kg 71.9 (19.0) 80.4 (17.4)** 80.8 (18.5)** 76.5 (19.1)**
HADS anxiety 11.8 (3.5) 8.9 (2.2)** 11.5 (2.6) 10.8 (2.5)
HADS depression 9.8 (1.8) 9.9 (1.7) 9.9 (1.8) 10.3 (2.0)
SF-36 physical 36.7 (8.9) 36.9 (8.1) 36.2 (8.6) 35.6 (9.5)
SF-36 psychomental 47.4 (11.5) 48.5 (11.8) 44.8 (11.4) 45.7 (11.3)
SGRQ-total score 57.5 (10.9) 57.7 (10.0) 56.2 (11.1) 55.1 (11.1)
MRC 2.0 (1.0) 1.7 (0.9) 1.9 (0.8) 2.1 (0.8)
BDI/TDI 6.93 (2.30) 6.34 (3.08) 4.98 (3.99) 3.78 (4.67)
Mean values and SD (in parentheses) are given. * p < 0.05 for improvement compared to pre-PR values,
** p < 0.01. PR = Pulmonary rehabilitation; for other abbreviations see table 1.
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 The improvements in the physical SF-36 subscale in 
asthma patients ( table 3 a) were maintained over 3 months 
(T4; p  ! 0.05) but not 12 months. Scores of all other ques-
tionnaires or questionnaire scores in other disease groups 
did not change significantly from baseline.
 The number of exacerbations and the use of the health 
care system for treatment of respiratory problems, i.e. 
hospital admissions, doctors consultations and need for 
antibiotic courses, are displayed in  table 4 . Reductions in 
these parameters occurred in all disease groups. The 
changes were statistically significant in the overall group 
c Results in asbestosis patients
Asbestosis (n = 66)
T1/T2 T3 T4 T5
FEV1%pred 76.6 (20.0) 74.7 (21.5)* 74.1 (22.3)* 73.8 (21.9)*
FVC%pred 81.2 (17.9) 80.9 (17.8) 80.6 (18.6) 80.6 (18.1)
Tiffeneau, %pred 94.6 (12.6) 94.0 (14.0) 93.4 (16.0) 92.8 (15.0)
Pimax 6.8 (2.8) 6.3 (2.8) 6.7 (2.7) 6.7 (2.5)
P0,1/Pimax 0.04 (0.02) 0.05 (0.03) 0.04 (0.03) 0.04 (0.03)
6MWD, m 504.7 (88.7) 507.6 (83.7) 497.0 (71.6) 483.5 (74.6)**
Borg 6MWD 3.8 (2.1) 3.8 (1.9) 4.3 (2.0) 4.7 (1.9)**
Wmax, W 107.7 (23.7) 115.2 (23.9)** 112.2 (24.4)** 111.7 (28.1)
Quadriceps force, kg 61.5 (19.9) 71.6 (22.0)** 72.9 (20.7)** 69.5 (21.1)**
Handgrip force, kg 69.9 (18.3) 77.3 (17.0)** 76.4 (16.4)** 75.6 (19.1)**
HADS anxiety 11.2 (3.5) 9.1 (2.0)** 11.1 (2.2) 11.2 (2.6)
HADS depression 9.9 (1.9) 10.0 (1.6) 10.0 (1.5) 10.0 (1.5)
SF-36 physical 35.8 (9.6) 36.4 (8.6) 38.8 (9.3)* 36.7 (9.3)
SF-36 psychomental 46.9 (12.8) 48.8 (11.9) 46.6 (10.6) 48.3 (10.5)
SGRQ-total score 56.8 (12.0) 55.7 (10.5) 56.1 (11.9) 55.6 (11.6)
MRC 1.8 (1.0) 1.8 (0.8) 1.8 (0.8) 2.0 (0.9)
BDI/TDI 7.01 (2.41) 6.21 (3.30) 5.43 (4.10) 3.99 (4.78)
d Results in COPD patients
COPD (n = 34)
T1/T2 T3 T4 T5
FEV1%pred 77.9 (19.2) 79.8 (17.6) 77.0 (20.0) 77.9 (19.9)
FVC%pred 92.1 (20.2) 93.8 (20.0) 92.6 (18.4) 91.8 (18.7)
Tiffeneau, %pred 84.2 (11.7) 86.2 (12.3) 84.9 (12.6) 87.0 (12.8)
Pimax 6.2 (1.6) 6.0 (1.9) 6.2 (1.9) 6.2 (2.3)
P0,1/Pimax 0.03 (0.02) 0.03 (0.02) 0.03 (0.02) 0.04 (0.05)
6MWD, m 435.8 (82.2) 468.6 (72.4)** 459.3 (75.3)** 452.0 (66.9)**
Borg 6MWD 4.0 (1.6) 4.4 (2.0) 3.9 (2.1) 5.3 (2.3)**
Wmax, W 108.8 (35.6) 115.6 (35.9)** 115.0 (31.9)** 115.9 (28.4)**
Quadriceps force, kg 54.9 (24.9) 68.7 (25.0)** 70.4 (25.0)** 64.9 (23.0)**
Handgrip force, kg 68.5 (15.2) 77.0 (14.6)** 78.1 (13.5)** 74.4 (14.4)**
HADS anxiety 11.2 (3.2) 8.7 (1.7)** 11.1 (2.3) 11.4 (1.9)
HADS depression 9.1 (1.8) 9.2 (1.6) 9.8 (1.8) 9.6 (1.5)
SF-36 physical 35.1 (9.2) 36.4 (11.1) 37.2 (10.4) 32.9 (7.9)
SF-36 psychomental 44.8 (11.9) 45.6 (10.4) 44.8 (11.1) 44.9 (10.3)
SGRQ-total score 53.4 (14.6) 54.8 (13.8) 55.9 (13.1) 52.4 (14.1)
MRC 1.9 (1.2) 1.8 (2.0) 1.9 (0.9) 1.9 (0.9)
BDI/TDI 7.35 (2.47) 6.12 (3.48) 5.41 (4.49) 4.24 (5.22)
Mean values and SD (in parentheses) are given. * p < 0.05 for improvement compared to pre-PR values,
** p < 0.01. PR = Pulmonary rehabilitation; for other abbreviations see table 1.
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(p  ! 0.05), showing a 35% reduction in exacerbations, 
27% for antibiotic courses and 17% for physician consul-
tations due to respiratory problems.
 Analysis Stratified according to Baseline Values 
 When patients were stratified according to their base-
line 6MWD, which was used as an indicator of function-
al capacity prior to rehabilitation, the relative changes of 
6MWD, quadriceps force and Wmax were higher in pa-
tients with greater impairment at baseline ( fig. 1 ). Patients 
with a baseline 6MWD exceeding 500 m demonstrated 
higher baseline values of FEV 1 %pred and FVC%pred, 
quadriceps force and Wmax (p  ! 0.05 for each, ANOVA) 
compared to those with lower baseline 6MWD. Whereas 
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 Fig. 1. Changes in physical performance after rehabilitation and at follow-up after 3 and 12 months as a function of the 6MWD prior 
to rehabilitation (pre-PR). pre-PR = Baseline values before pulmonary rehabilitation (T1/T2);   T3,   T4,   T5 = respective differences 
in relation to baseline values (T1/T2). For other abbreviations see table 1 and 3. 
Table 4. Respiratory infections and utilization of health care services, the number of incidents per person before and after pulmonary 
rehabilitation
Total Asthma Silicosis Asbestosis  COPD
 pre post pre post pre post pre post pre post
Respiratory infections 1.53 0.99* 1.77 1.26* 1.33 0.80 1.14 0.78 1.68 0.71*
Physician consultations 1.35 1.12* 1.99 1.62 0.83 0.55 0.70 0.83 1.06 0.65
Antibiotic courses 0.66 0.48* 0.82 0.66 0.43 0.23 0.44 0.40 0.81 0.31*
Hospital admissions 0.13 0.06* 0.16 0.10 0.10 0.03 0.08 0.03 0.15 0
* p < 0.05 for improvement compared to pre-PR values, ** p < 0.01. pre = Values in the 12 months before pulmonary rehabilitation; 
post = values in the 12 months after pulmonary rehabilitation.
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muscle force and Wmax increased in these patients, no 
improvement was seen in 6MWD.
 Of the 99 patients who did not report any exacerba-
tions in the 12 months prior to rehabilitation, 55 remained 
without, 35 experienced one, and 9 experienced two or 
more exacerbations afterwards.  Figure 2 shows a stratified 
analysis of patients having reported  6 1 exacerbation in 
the 12 months before rehabilitation. Baseline lung func-
tion and 6MWD did not differ between the categories. 
There was a significant reduction in the number of respi-
ratory infections, doctors consultations and courses of an-
tibiotics in nearly all exacerbation categories (p  ! 0.05). In 
patients previously reporting  6 3 exacerbations, the effect 
on respiratory exacerbation rate was most pronounced.
 Discussion 
 This prospective study demonstrated substantial 
short- and long-term effects of a 4-week inpatient pulmo-
nary rehabilitation program in a large group of patients 
with different occupational respiratory diseases. While 
acute improvements were relatively similar between dis-
eases, the persistence of effects over a period of 12 months 
after rehabilitation differed. The secondary outcomes 
(number of respiratory infections, antibiotic courses, vis-
its to a doctor due to the underlying lung disease) were 
also significantly reduced, indicating an overall improve-
ment of the health status.
 There is strong evidence that pulmonary rehabilita-
tion improves physical performance, psychosocial situa-
tion and dyspnea  [1] . These domains interact with each 
other – physical impairment affects self-reliance, quality 
of life and dyspnea. Depression, anxiety and dyspnea fa-
vor inactivity, and dyspnea increases anxiety. To cover as 
many of these changes as possible we chose a broad pan-
el of functional and psychosocial measures.
 Due to the underlying pathophysiology, a persistent 
improvement in lung function is unlikely to occur after 
rehabilitation. However, optimized medication, better 
compliance and daily physical activity may have a long-
term impact. Thus, clinically important effects such as 
reductions in exacerbation rates and reduced use of health 
care resources were included. 
 Short-Term Effects 
 Impaired exercise tolerance is common in chronic 
lung diseases. Beyond airflow limitations and reductions 
in lung volume and gas exchange, skeletal muscle weak-
ness is recognized as a causal factor  [7–9] . Improvement 
of physical performance can break the vicious circle in-
duced by inactivity leading to deconditioning, loss of 
functional capacity in daily life and indirectly to depres-
sion and poor quality of life. Regarding physical perfor-
mance, our results confirm that intensified endurance 
and resistance training in combination with therapeutic 
and educational sessions over 4 weeks is capable of im-
proving exercise capacity and muscle strength, irrespec-
tive of the underlying pulmonary disease. Peripheral 
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1 infection pre-PR (n = 60)
FEV1%pred 79 (21)
FVC%pred 89 (20) 
2 infections pre-PR (n = 51)
FEV1%pred 79 (22)
FVC%pred 93 (21) 
≥3 infections pre-PR (n = 52) 
 FEV1%pred 76 (20)
FVC%pred 88 (19) 
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 Fig. 2. Reduction of respiratory infections 
and use of health care services as a func-
tion of the rate of respiratory infections 
prior to rehabilitation (pre-PR). pre-PR = 
Baseline values before pulmonary rehabil-
itation; post-PR = values 12 months after 
pulmonary rehabilitation. FEV 1 %pred and 
FVC%pred values are mean (SD).  *   p  ! 
0.05 for reduction compared to pre-PR val-
ues,  * *  p  ! 0.01, ns = non-significant. 
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muscle strength as well as 6MWD improved. As the ab-
solute improvement of muscle strength was independent 
of baseline values, patients displaying lower strength at 
baseline had greater relative gain.
 Endurance and resistance training act synergistically 
on exercise tolerance, and 6MWD is known to improve 
after resistance training  [10, 11] . Besides dyspnea, the 
dominant symptom limiting exercise capacity appears to 
be leg effort, as indicated by its correlation with dyspnea, 
muscle strength and exercise tolerance  [12] . Correspond-
ingly, a 2-fold increase in muscle strength was associated 
with a decrease of dyspnea and the sensation of intoler-
able leg effort and a 1.5-fold increase in work capacity  [9] .
 Both 6MWD and maximum workload by ergometer 
testing address exercise tolerance. There was a negative 
correlation between baseline values and change in 
6MWD, which is consistent with previous data  [13] . 
While 6MWD is sensitive in patients with advanced pul-
monary impairment, its informative value is lower in less 
impaired patients due to a ceiling effect, which is differ-
ent to maximum workload. This suggests that both meth-
ods should be used in populations with varying severity 
of disease.
 COPD  [14, 15] as well as asthma  [16] are associated 
with anxiety and depression. In our study the HADS 
questionnaire  [17] revealed unexpectedly high scores. 
About 90% of patients displayed a depressive mood at 
baseline according to threshold values from the literature 
 [18–20] . The score for depression remained unchanged, 
contrary to previous observations  [15] . Concerning anxi-
ety, there was a short benefit of rehabilitation reflected by 
an average improvement of 2.5 points, which exceeded 
the previously reported 1.3 and 0.8 points  [18, 19] .
 Both the SGRQ and SF-36 questionnaires indicated a 
lower quality of life at baseline than expected from lung 
function, age and disease  [21–24] . No clinically relevant 
changes were observed after rehabilitation. The explana-
tion might be the specific psychosocial situation in occu-
pational diseases. Subjects are often forced to give up 
their occupation, with the risk of unemployment and loss 
of social standing. A reduced quality of life has already 
been reported in patients with occupational asthma com-
pared to asthma of nonoccupational etiology  [25–27] . 
Overall, the high level of depression may be responsible 
for the reduced quality of life and the lack of change in 
our study population.
 According to the MRC and BDI/TDI values, we did 
not observe an improvement in dyspnea, in contrast to 
the literature  [1] . Dyspnea is known to be a complex sen-
sation that is affected by the discrepancy between an in-
creased respiratory drive during exercise and the inabil-
ity to appropriately increase tidal volume. Chronic bron-
choconstriction and a long duration of disease may lead 
to desensitization concerning the perceived information. 
For example, in asthma the perception of dyspnea has 
been found to be negatively correlated to disease severity 
and depression status  [28] . No plausible associations were 
found between functional measures and dyspnea scores 
in our study. This suggests that in our specific popula-
tion, psychosocial factors played an important role, un-
derlining the importance of objective measures to quan-
tify the effects of rehabilitation.
 Long-Term Effects 
 One aim of pulmonary rehabilitation is to sustain the 
acute effects. The improvement in peripheral muscle 
strength was maintained over 1 year in almost all pa-
tients, independent of baseline levels and disease. In ob-
structive diseases, i.e. asthma and COPD, and in com-
bined ventilatory disorders due to silicosis, the improve-
ments in Wmax and 6MWD were comparable and 
long-lasting. Patients with restrictive impairment due to 
asbestosis showed minor benefits; 6MWD did not im-
prove at all, and the gain in Wmax lasted only 3 months, 
corresponding to other results for the rehabilitation of 
patients with interstitial lung disease  [4, 5] .
 The study by van Wetering et al.  [29] seems to be most 
similar to our study; however, these authors compared 
their intervention group with a control group. When 
evaluating their data versus baseline, the increase of cy-
cling endurance time was maintained during follow-up. 
Both SGRQ total score and MRC score improved imme-
diately after intervention but the first had decreased to 
baseline by 8 months and the second by 20 months. 
6MWD never exceeded baseline and worsened over the 
follow-up. 
 Concerning pulmonary rehabilitation in occupational 
respiratory diseases, only patients with asbestosis have 
been previously evaluated  [30, 31] using a 3-week intensi-
fied outpatient program followed by a 3-month mainte-
nance program. This improved quadriceps muscle 
strength and 6MWD; ergometer testing was not conduct-
ed. During follow-up, only patients continuing physical 
activity maintained the effects of rehabilitation, while the 
others returned to baseline within 6 months. These re-
sults correspond with our findings.
 Besides the maintenance of acute effects, the second-
ary long-term outcomes, i.e. the rate of exacerbations and 
the use of health care resources, are also important  [29, 
32–36] . About half of the rehabilitation studies revealed 
 Ochmann  /Kotschy-Lang  /Raab  /
Kellberger  /Nowak  /Jörres  
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statistically significant improvements in these measures 
 [6] . Patients with pulmonary diseases are particularly 
susceptible to respiratory infections, leading to exacerba-
tions as reflected by a worsening of lung function, addi-
tional medications and absence from the workplace. In 
COPD, the frequency of exacerbations correlates with 
disease severity, lung function decline and mortality  [37] , 
and self-reported exacerbations predict future exacerba-
tions  [38, 39] . As a minimal clinically important differ-
ence, a 20% reduction in incidents per year has been sug-
gested for clinical trials  [40] . Moreover, in COPD a med-
ication-induced reduction of annual exacerbations by 
11% was recently considered as clinically relevant  [32] .
 We determined the self-reported rates of acute exacer-
bations, respiratory problems requiring physician visits, 
prescribed antibiotic courses, as well as the number and 
duration of hospital stays within 12 months before and 
after rehabilitation, showing a statistically significant re-
duction in the total group. The annual rate of exacerba-
tions was reduced by 35% and this was especially appar-
ent in patients with a higher baseline rate. In our study 
collective with less advanced impairment, hospital ad-
missions due to respiratory illness were rare but even 
these showed a reduction.
 Pulmonary rehabilitation has been discussed as a fac-
tor in reducing exacerbation rates in COPD  [37, 41] . This 
positive effect has not been reported previously in asthma 
or interstitial lung disease. Regarding structural changes 
of the bronchial system, silicosis bears similarities to 
COPD, thus a reduction of the exacerbation rate should 
be of comparable relevance. In asthma, severe acute ex-
acerbations are responsible for the major part of the dis-
ease-related health burden  [42] , showing a strong asso-
ciation with respiratory infections  [43] . The role of respi-
ratory infections in asbestosis is not clear. In our 
population, the rate at baseline was significantly lower in 
comparison with the other groups, suggesting a lower rel-
evance.
 Limitations of the Study 
 Due to ethical and legal considerations, the rehabilita-
tion of patients entitled to receive rehabilitation could not 
be postponed for more than 1 year. In Germany, reha-
bilitation is an enforceable claim as part of compensation 
in occupational diseases. This prevented us from creating 
a matched control group without rehabilitation. Our goal 
of studying whether improvements are sustained and 
how effects compare between diseases did not seem to 
require a randomized, control-group design. The longi-
tudinal analysis with two follow-up visits also provided 
the greatest statistical power to detect long-term benefits 
and their minimum duration.
 Enrollment was organized by 15 social accident insur-
ance companies, which were asked to search their data-
base according to the inclusion criteria. The investigators 
did not have an influence on the recruitment and do not 
have information regarding the total numbers of patients 
fulfilling the criteria or asked to or refusing to partici-
pate. However, the study population does not obviously 
differ from the occupational compensation cases seen in 
our outpatient clinic and the rehabilitation clinics.
 The rather small proportion of females can be attrib-
uted to the prevalence of male-dominated occupations 
associated with the evaluated occupational diseases. The 
group sizes also differed, mainly because the age of pa-
tients with silicosis and of coal miners often exceeds 70 
years and a considerable number of these patients un-
dergo annual rehabilitation.
 Conclusion and Perspective 
 Our results indicate that in occupational respiratory 
diseases, an inpatient pulmonary rehabilitation program 
is capable of improving physical capacity and exacerba-
tion rates over at least 1 year. Probably a subsequent 
maintenance program, e.g. as provided by sport groups, 
could support maintaining these functional effects. It 
could also have an impact on exacerbation rates and the 
use of health care resources, with the potential to influ-
ence the course of the disease. This should be evaluated 
in future studies on pulmonary rehabilitation in occupa-
tional diseases. 
 Acknowledgements 
 This study was supported and approved by DGUV, German 
Social Accident Insurance (registered umbrella association of the 
accident insurance institutions for the industrial and public sec-
tors).
 
 References  1 Ries AL: Pulmonary rehabilitation: summa-
ry of an evidence-based guideline. Respir 
Care 2008; 53: 1203–1207. 
 2 Emtner M, Finne M, Stalenheim G: A 3-year 
follow-up of asthmatic patients participating 
in a 10-week rehabilitation program with 
emphasis on physical training. Arch Phys 
Med Rehabil 1998; 79: 539–544. 
 3 Turner S, Eastwood P, Cook A, Jenkins S: Im-
provements in symptoms and quality of life 
following exercise training in older adults 
with moderate/severe persistent asthma. 
Respiration 2011; 81: 302–310. 
 Pulmonary Rehabilitation in 
Occupational Lung Disease 
Respiration 2012;84:396–405 405
 4 Naji NA, Connor MC, Donnelly SC, McDon-
nell TJ: Effectiveness of pulmonary rehabili-
tation in restrictive lung disease. J Cardio-
pulm Rehabil 2006; 26: 237–243. 
 5 Kozu R, Senjyu H, Jenkins SC, Mukae H, 
Sakamoto N, Kohno S: Differences in re-
sponse to pulmonary rehabilitation in idio-
pathic pulmonary fibrosis and chronic ob-
structive pulmonary disease. Respiration 
2011; 81: 196–205. 
 6 Ochmann U, Jorres RA, Nowak D: Long-
term efficacy of pulmonary rehabilitation: a 
state-of-the-art review. J Cardiopulm Reha-
bil Prev 2012;32:117–126. 
 7 Man WD, Kemp P, Moxham J, Polkey MI: 
Exercise and muscle dysfunction in COPD: 
implications for pulmonary rehabilitation. 
Clin Sci (Lond) 2009; 117: 281–291. 
 8 Nishiyama O, Kondoh Y, Kimura T, Kato K, 
Kataoka K, Ogawa T, Watanabe F, Arizono S, 
Nishimura K, Taniguchi H: Effects of pul-
monary rehabilitation in patients with idio-
pathic pulmonary fibrosis. Respirology 
2008; 13: 394–399. 
 9 Gosselink R, Troosters T, Decramer M: Pe-
ripheral muscle weakness contributes to ex-
ercise limitation in COPD. Am J Respir Crit 
Care Med 1996; 153: 976–980. 
 10 Troosters T, Probst VS, Crul T, Pitta F, Gay-
an-Ramirez G, Decramer M, Gosselink R: 
Resistance training prevents deterioration in 
quadriceps muscle function during acute ex-
acerbations of chronic obstructive pulmo-
nary disease. Am J Respir Crit Care Med 
2010; 181: 1072–1077. 
 11 Spruit MA, Gosselink R, Troosters T, De 
Paepe K, Decramer M: Resistance versus en-
durance training in patients with COPD and 
peripheral muscle weakness. Eur Respir J 
2002; 19: 1072–1078. 
 12 Hamilton AL, Killian KJ, Summers E, Jones 
NL: Symptom intensity and subjective limita-
tion to exercise in patients with cardiorespira-
tory disorders. Chest 1996; 110: 1255–1263. 
 13 Ferreira G, Feuerman M, Spiegler P: Results 
of an 8-week, outpatient pulmonary rehabil-
itation program on patients with and with-
out chronic obstructive pulmonary disease. 
J Cardiopulm Rehabil 2006; 26: 54–60. 
 14 Mikkelsen RL, Middelboe T, Pisinger C, 
Stage KB: Anxiety and depression in patients 
with chronic obstructive pulmonary disease 
(COPD): a review. Nord J Psychiatry 2004; 
 58: 65–70. 
 15 Coventry PA: Does pulmonary rehabilita-
tion reduce anxiety and depression in chron-
ic obstructive pulmonary disease? Curr 
Opin Pulm Med 2009; 15: 143–149. 
 16 Carvalho NS, Ribeiro PR, Ribeiro M, Nunes 
Mdo P, Cukier A, Stelmach R: Comparing 
asthma and chronic obstructive pulmonary 
disease in terms of symptoms of anxiety and 
depression. J Bras Pneumol 2007; 33: 1–6. 
 17 Putman-Casdorph H, McCrone S: Chronic 
obstructive pulmonary disease, anxiety, and 
depression: state of the science. Heart Lung 
2009; 38: 34–47. 
 18 Griffiths TL, Burr ML, Campbell IA, Lewis-
Jenkins V, Mullins J, Shiels K, Turner-Lawlor 
PJ, Payne N, Newcombe RG, Ionescu AA, 
Thomas J, Tunbridge J: Results at 1 year of 
outpatient multidisciplinary pulmonary re-
habilitation: a randomised controlled trial. 
Lancet 2000; 355: 362–368. 
 19 White RJ, Rudkin ST, Harrison ST, Day KL, 
Harvey IM: Pulmonary rehabilitation com-
pared with brief advice given for severe 
chronic obstructive pulmonary disease. J 
Cardiopulm Rehabil 2002; 22: 338–344. 
 20 Janssen DJ, Spruit MA, Leue C, Gijsen C, 
Hameleers H, Schols JM, Wouters EF: Symp-
toms of anxiety and depression in COPD pa-
tients entering pulmonary rehabilitation. 
Chron Respir Dis 2010; 7: 147–157. 
 21 Jastrzebski D, Gumola A, Gawlik R, Koziel-
ski J: Dyspnea and quality of life in patients 
with pulmonary fibrosis after six weeks of 
respiratory rehabilitation. J Physiol Pharma-
col 2006; 57(suppl 4):139–148. 
 22 Buss AS, Silva LM: Comparative study of two 
quality of life questionnaires in patients with 
COPD. J Bras Pneumol 2009; 35: 318–324. 
 23 Jones PW, Brusselle G, Dal Negro RW, Ferrer 
M, Kardos P, Levy ML, Perez T, Soler-Cata-
luna JJ, van der Molen T, Adamek L, Banik 
N: Health-related quality of life in patients by 
COPD severity within primary care in Eu-
rope. Respir Med 2011; 105: 57–66. 
 24 Bullinger M, Kirchberger I (eds): Der SF-36-
Fragebogen zum Gesundheitszustand: 
Handbuch für die deutschsprachige Frage-
bogenversion. Göttingen, Hogrefe, 1997. 
 25 Dimich-Ward H, Taliadouros V, Teschke K, 
Chow Y, Abboud R, Chan-Yeung M: Quality 
of life and employment status of workers 
with western red cedar asthma. J Occup En-
viron Med 2007; 49: 1040–1045. 
 26 Lowery EP, Henneberger PK, Rosiello R, 
Sama SR, Preusse P, Milton DK: Quality of 
life of adults with workplace exacerbation of 
asthma. Qual Life Res 2007; 16: 1605–1613. 
 27 Lavoie KL, Joseph M, Bacon SL: Psychologi-
cal distress and occupational asthma. Curr 
Opin Allergy Clin Immunol 2009; 9: 103–109. 
 28 Foschino Barbaro MP, Lacedonia D, Palla-
dino GP, Bergantino L, Ruggeri C, Martinel-
li D, Carpagnano GE: Dyspnea perception in 
asthma: role of airways inflammation, age 
and emotional status. Respir Med 2010; 105: 
 195–203. 
 29 van Wetering CR, Hoogendoorn M, Mol SJ, 
Rutten-van Molken MP, Schols AM: Short- 
and long-term efficacy of a community-
based COPD management programme in 
less advanced COPD: a randomised con-
trolled trial. Thorax 2010; 65: 7–13. 
 30 Dalichau S, Demedts A, im Sande A, Möller 
T: Improvement of lasting effects in outpa-
tient pulmonary rehabilitation with special 
regard to exercise therapy and sports (in 
German). Rehabilitation (Stuttg) 2010; 49: 
 30–37. 
 31 Dalichau S, Demedts A, im Sande A, Moller 
T: Short- and long-term effects of the outpa-
tient medical rehabilitation for patients with 
asbestosis (in German). Pneumologie 2010; 
 64: 163–170. 
 32 Vogelmeier C, Hederer B, Glaab T, Schmidt 
H, Rutten-van Molken MP, Beeh KM, Rabe 
KF, Fabbri LM: Tiotropium versus salmeter-
ol for the prevention of exacerbations of 
COPD. N Engl J Med 2011; 364: 1093–1103. 
 33 Al Moamary MS: Health care utilization 
among chronic obstructive pulmonary dis-
ease patients and the effect of pulmonary reha-
bilitation. Med Princ Pract 2010; 19: 373–378. 
 34 Rice KL, Dewan N, Bloomfield HE, Grill J, 
Schult TM, Nelson DB, Kumari S, Thomas 
M, Geist LJ, Beaner C, Caldwell M, Niewoeh-
ner DE: Disease management program for 
chronic obstructive pulmonary disease: a 
randomized controlled trial. Am J Respir 
Crit Care Med 2010; 182: 890–896. 
 35 Rubi M, Renom F, Ramis F, Medinas M, 
Centeno MJ, Gorriz M, Crespi E, Martin B, 
Soriano JB: Effectiveness of pulmonary re-
habilitation in reducing health resources use 
in chronic obstructive pulmonary disease. 
Arch Phys Med Rehabil 2010; 91: 364–368. 
 36 Spencer LM, Alison JA, McKeough ZJ: 
Maintaining benefits following pulmonary 
rehabilitation: a randomised controlled trial. 
Eur Respir J 2010; 35: 571–577. 
 37 Seemungal TA, Hurst JR, Wedzicha JA: Ex-
acerbation rate, health status and mortality 
in COPD – a review of potential interven-
tions. Int J Chron Obstruct Pulmon Dis 
2009; 4: 203–223. 
 38 Anzueto A: Impact of exacerbations on 
COPD. Eur Respir Rev 2010; 19: 113–118. 
 39 Hurst JR, Vestbo J, Anzueto A, Locantore N, 
Mullerova H, Tal-Singer R, Miller B, Lomas 
DA, Agusti A, Macnee W, Calverley P, Ren-
nard S, Wouters EF, Wedzicha JA: Suscepti-
bility to exacerbation in chronic obstructive 
pulmonary disease. N Engl J Med 2010; 363: 
 1128–1138. 
 40 Calverley PM: Minimal clinically important 
difference – exacerbations of COPD. COPD 
2005; 2: 143–148. 
 41 Anzueto A: Primary care management of 
chronic obstructive pulmonary disease to 
reduce exacerbations and their consequenc-
es. Am J Med Sci 2010; 340: 309–318. 
 42 Dougherty RH, Fahy JV: Acute exacerba-
tions of asthma: epidemiology, biology and 
the exacerbation-prone phenotype. Clin Exp 
Allergy 2009; 39: 193–202. 
 43 Papadopoulos NG, Xepapadaki P, Mallia P, 
Brusselle G, Watelet JB, Xatzipsalti M, Fo-
teinos G, van Drunen CM, Fokkens WJ, 
D’Ambrosio C, Bonini S, Bossios A, Lotvall 
J, van Cauwenberge P, Holgate ST, Canonica 
GW, Szczeklik A, Rohde G, Kimpen J, Pit-
karanta A, Makela M, Chanez P, Ring J, 
Johnston SL: Mechanisms of virus-induced 
asthma exacerbations: state-of-the-art – A 
GA2LEN and InterAirways document. Al-
lergy 2007; 62: 457–470. 
 
